Biologic Drugs, Biosimilars, and Barriers to Entry

Area of Science:

• Pharmaceuticals
• Health Economics
• Regulatory Affairs

Background:

• Biologic drugs offer significant health benefits but are often prohibitively expensive.
• Biosimilars, or generic biologic substitutes, were developed to increase access and reduce costs.
• A regulatory pathway for biosimilar approval has been established.

Purpose of the Study:

• To explore the conflict between original biologic manufacturers and biosimilars.
• To analyze the impact of legal and regulatory barriers on biosimilar market entry.
• To examine the consequences of limited biosimilar competition on drug costs and patient access.

Main Methods:

• Review of legal and regulatory strategies employed by original biologic manufacturers.
• Analysis of market dynamics and competition in the biologic drug sector.
• Examination of the impact on drug innovation and patient access.

Main Results:

• Original biologic manufacturers are actively creating barriers to delay biosimilar approval and market entry.
• These tactics include legal challenges, circumventing naming protocols, and undermining substitution.
• Such actions reduce market competition, stifle innovation, and increase drug costs.

Conclusions:

• Barriers to biosimilar entry limit competition, impede innovation, and restrict patient access to affordable biologic medications.
• The strategies employed by original manufacturers undermine the intended benefits of the biosimilar pathway.
• Addressing these barriers is crucial for improving healthcare outcomes and reducing drug expenditures.